Quinn Opportunity Partners LLC Has $363,000 Stake in Heron Therapeutics, Inc. $HRTX

Quinn Opportunity Partners LLC reduced its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 37.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 175,344 shares of the biotechnology company’s stock after selling 104,656 shares during the period. Quinn Opportunity Partners LLC owned about 0.11% of Heron Therapeutics worth $363,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. AIGH Capital Management LLC bought a new stake in shares of Heron Therapeutics during the first quarter valued at approximately $6,112,000. New York State Common Retirement Fund raised its position in shares of Heron Therapeutics by 32.7% in the first quarter. New York State Common Retirement Fund now owns 1,752,924 shares of the biotechnology company’s stock valued at $3,856,000 after purchasing an additional 431,918 shares during the period. TD Asset Management Inc purchased a new stake in Heron Therapeutics during the 1st quarter worth about $868,000. Goldman Sachs Group Inc. grew its position in shares of Heron Therapeutics by 57.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,028,678 shares of the biotechnology company’s stock valued at $2,263,000 after purchasing an additional 373,518 shares in the last quarter. Finally, Informed Momentum Co LLC bought a new stake in Heron Therapeutics during the first quarter valued at approximately $768,000. 80.01% of the stock is currently owned by institutional investors and hedge funds.

Heron Therapeutics Trading Down 4.3%

NASDAQ HRTX opened at $1.11 on Thursday. Heron Therapeutics, Inc. has a 12 month low of $1.05 and a 12 month high of $2.68. The stock has a market cap of $203.53 million, a price-to-earnings ratio of -55.50 and a beta of 1.30. The company’s 50 day moving average is $1.24 and its two-hundred day moving average is $1.66.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03). The firm had revenue of $38.21 million for the quarter, compared to analysts’ expectations of $39.03 million. Heron Therapeutics has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Analyst Ratings Changes

Several analysts have weighed in on HRTX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Wednesday, October 8th. Needham & Company LLC dropped their target price on shares of Heron Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Zacks Research raised Heron Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 7th. Wall Street Zen cut Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Heron Therapeutics in a report on Tuesday, November 4th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $4.50.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.